A recent study from the University of Michigan Health Rogel Cancer Center, led by Dr. Arul M. Chinnaiyan, identifies the UBA1 enzyme as a critical factor in tumor resistance to immunotherapy. The research suggests that inhibiting UBA1 could boost T-cell recruitment to tumors, enhancing the effectiveness of treatments, particularly for “cold” tumors like prostate cancer. This breakthrough may pave the way for new combination therapies, potentially expanding the reach of immune checkpoint blockade to more patients.
